What is the market's earnings forecast for ADMA Biologics next quarter?

Did ADMA Biologics beat or miss consensus estimates last quarter?

What were the key takeaways from ADMA Biologics's earnings call?

What factors drove the changes in ADMA Biologics's revenue and profit?

What guidance did ADMA Biologics's management provide for the next earnings period?

What is ADMA Biologics's latest dividend and current dividend yield?

What were the key takeaways from ADMA Biologics’s earnings call?

What does ADMA Biologics do and what are its main business segments?

- **Record Q3 Results**: $134.2M revenue (12% YoY), $36.4M net income, $58.7M EBITDA (29% YoY growth).
- **ASCENIV Clinical Success**: 50%+ infection reduction data to be published, driving 2026 payer expansion.
- **Yield-Enhanced Production**: 20%+ output increase, targeting 70%+ gross margin by 2026.
- **Updated Guidance**: 2026 revenue up to $630M+, 2029 target >$1.1B.
- **High-Growth Pipeline**: SG001 potential $300-$500M annual revenue by 2029.

**【CEO Summary Section】**
- ADMA reported total revenue of $134.2 million for Q3 2025, up 10% QoQ and 12% YoY, driven by ASCENIV's record utilization.
- GAAP net income reached $36.4 million (up 6% QoQ, 1% YoY), with adjusted EBITDA at $58.7 million (16% QoQ growth, 29% YoY).
- ASCENIV demonstrated a 50%+ reduction in infections (2.1 to 0.9 per year) in a retrospective study, with plans for peer-reviewed publication and 2026 clinical meeting presentations.
- FDA-approved yield-enhanced production batches increased per-batch output by 20%+, with full 2026 production expected to drive gross margin expansion.
- SG001 program submitted Priority Review Voucher application; preclinical data shows broader serotype coverage than existing vaccines, targeting a $300-$500M annual revenue opportunity by 2029.
- Share repurchases of $23M in Q3, with $225M undrawn revolver supporting capital deployment.

**【CFO Financial Commentary】**
- Q3 2025: 
  - Total revenue: $134.2M (10% QoQ, 12% YoY)
  - Gross margin: 56.3% (vs. 49.8% YoY), product-level margin 63.7% (excluding $13.8M plasma sale)
  - GAAP net income: $36.4M (1% YoY), adjusted EBITDA: $58.7M (29% YoY)
- Updated 2025 guidance: 
  - Revenue: $510M (vs. prior $500M+)
  - Adjusted net income: $158M (modestly adjusted due to higher tax rate)
  - Adjusted EBITDA: $235M
- 2026 outlook: 
  - Revenue: $630M+ (vs. prior $625M+)
  - Adjusted net income: $255M+ (vs. prior $245M+)
  - Adjusted EBITDA: $355M+ (vs. prior $340M+)
- 2029 target: >$1.1B annual revenue, excluding SG001 contribution.

**【Q&A Key Highlights】**
- **ASCENIV clinical data impact**: 50%+ infection reduction data expected to accelerate payer access and utilization, with 2026 medical education campaigns planned.
- **Yield-enhanced production**: FDA lot release completed, with full 2026 production expected to drive 70%+ gross margin potential.
- **Payer negotiations**: Positive progress on ASCENIV coverage, with 40%-45% of utilization through commercial payers.
- **SG001 timeline**: IND submission anticipated, with potential 2029 launch and $300-$500M annual revenue opportunity.
- **Revenue growth trajectory**: 24% YoY revenue growth in 2026, driven by ASCENIV mix shift and yield-enhanced production efficiency.

ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript

- **Revenue Record**: Q2 2025 revenue of $122 million (+14% YoY), with ASCENIV adoption driving 29% adjusted growth. 
- **Margin Game-Changer**: FDA-approved yield enhancement process delivers 20%+ bulk IG yield, set to expand gross margins from early 2026. 
- **Debt Win**: $300 million refinancing cuts borrowing costs, with spreads as low as 1.5% for revolving credit. 
- **Growth Engine**: SG-001 preclinical success points to $300-500M annual opportunity, with clinical trials poised to accelerate. 
- **Cash Power**: $90.3M cash on hand, $15M share buybacks, and free cash flow positive despite inventory build.

**【CEO Summary Section】**
- **Record Q2 Revenue Growth**: Total revenue reached $122 million, up 14% YoY, with adjusted growth of 29% excluding a one-time Medicaid rebate reversal. ASCENIV utilization hit record highs, driving demand.
- **Yield Enhancement Success**: FDA-approved production process achieved 20%+ bulk IG yield increase, expected to expand gross margins starting in early 2026. Initial production batches are already showing results.
- **Debt Refinancing**: Completed $300 million JPMorgan-led credit facility, reducing borrowing costs and enhancing liquidity. Term loan spreads range from 2.5% to 3%, with revolving credit at 1.5% to 2%.
- **Infrastructure Expansion**: Acquired 5-acre Boca Raton facility for cold storage, testing, and potential 30% cGMP manufacturing expansion. Capital expenditures remain modest, with focus on long-term scalability.
- **Pipeline Progress**: SG-001 preclinical studies show promise for $300-500 million annual revenue potential. First data readouts expected to accelerate clinical development.

**【CFO Financial Commentary】**
- **Profitability Metrics**: Adjusted net income of $36 million (+85% YoY), adjusted EBITDA of $50.8 million (+59% YoY). Gross margin improved to 55.1%, up 1.5% YoY.
- **Cash Flow Strength**: Generated $90.3 million in cash, with $15 million in share buybacks under $500 million program. Free cash flow positive despite $19.3 million inventory build for ASCENIV production.
- **Guidance Reaffirmation**: 2025 targets: $500+ million revenue, $235 million EBITDA, $175 million net income. 2026 outlook: $625+ million revenue, $340 million EBITDA, $245 million net income. Excludes yield enhancement accretion in 2025.

**【Q&A Highlights】**
- **ASCENIV Utilization Trends**: New patient starts and physician adoption continue at strong rates, with same-store utilization growth. ASCENIV now used in ~100 clinics, targeting 300+ by end-2026.
- **Yield Process Details**: Waste stream repurposing adds 20%+ bulk IG, with no incremental cost. First enhanced batches expected to hit the market in Q4 2025.
- **Supply Chain Confidence**: External plasma suppliers (Grifols, Kedrion) exceeding expectations, with internal collection volumes at record levels. No supply constraints anticipated.
- **Gross Margin Outlook**: 2025 margin expansion driven by ASCENIV mix shift; 2026+ gains from yield enhancement and scale. No headwinds identified in current operations.
- **Facility Expansion Timing**: No immediate capacity expansion plans, but new facility provides flexibility for future growth (e.g., SG-001 commercialization).

ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript

- **Revenue Growth Supercharged**: Q1 2025 revenue up 40% YoY to $114.8M, with ASCENIV driving 45% adjusted growth.
- **Game-Changing Yield Enhancement**: FDA-approved 20% bulk IG output increase set to boost 2026 margins by 500+ basis points.
- **Guidance Hike**: 2025 revenue target raised to $500M+, 2030 outlook expanded to $1.1B, backed by $171M cash buffer.
- **Shareholder Returns**: $500M buyback program launched, complementing debt restructuring to cut cost of capital by 1.1%.
- **Supply Chain Resilience**: 250 new plasma centers reduce supply risk, enabling 2025 production ramp to meet 20%+ demand growth.

**【CEO Opening Remarks】**
- ADMA achieved **$114.8M in Q1 2025 revenue**, up 40% YoY, driven by ASCENIV sales growth and a favorable product mix shift.
- Introduced a **20% yield enhancement production process** for bulk immunoglobulin (IG), approved by FDA, enabling 20% more IG from same plasma volumes.
- Raised 2025 guidance to **$500M+ total revenue**, **$235M+ adjusted EBITDA**, and **$175M+ adjusted net income**.
- Expanded 2030 revenue target to **$1.1B**, up from $1B, citing supply chain resilience and demand growth.
- Announced a **$500M stock buyback program** (8% of current market cap) to return capital to shareholders.

**【CFO Financial Breakdown】**
- **Adjusted EBITDA**: $47.9M (81% YoY growth), **Adjusted Net Income**: $33.3M (87% YoY growth).
- **Gross Margin**: 53.2% (vs. 47.8% YoY), improving to 54.7% when excluding one-time product withdrawals.
- **Cash & Receivables**: $171M at end of Q1, providing liquidity buffer against market volatility.
- **Debt Optimization**: Reduced cost of debt by 1.1% via term loan restructuring with Ares Capital.

**【Q&A Highlights】**
1. **Yield Enhancement Rollout**: 3 conformance lots (2 BIVIGAM, 1 ASCENIV) manufactured for FDA approval; expects to release enhanced yield product in 2025H2 after clearing existing inventory.
2. **Demand & Supply**: ASCENIV backlog remains robust; new high-titer plasma supply agreements add ~250 plasma centers, reducing historical supply constraints.
3. **Capital Allocation**: Priorities include debt repayment, R&D (SG-001 for strep pneumonia), and share buybacks, enabled by projected $100M+ annual free cash flow.
4. **IP Extension**: Potential to extend ASCENIV IP beyond 2035 via novel manufacturing methods; current portfolio has >10 years of exclusivity.
5. **Patient Access**: HEOR data expected Q4 2025 to demonstrate ASCENIV's cost-saving benefits vs. standard IG; payer access remains strong with no government price controls.

**【Financial Guidance Updates】**
- **2026 Outlook**: $625M+ revenue, $340M+ EBITDA, $245M+ net income, driven by enhanced yield production and ASCENIV mix shift.
- **Long-Term Vision**: Target $1B+ annual revenue by 2030, with >50% gross margins sustained through 2035 via branded durability and supply chain control.

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

- **Record Financial Growth**: 2024 revenue up 65% to $426.5M, with EBITDA surging 309% to $164.6M. 2025 guidance raised to $490M+ revenue and $225M+ EBITDA.
- **ASCENIV Dominance**: ASCENIV now 80%+ of revenue, with 3% market penetration and 1,000+ new patients queued. Potential $1B+ annual sales by 2030.
- **Supply Chain Expansion**: Fivefold plasma collection capacity increase via third-party contracts, enabling 20%+ production yield enhancement if FDA approves mid-2025.
- **Pipeline Momentum**: SG-001 anti-strep therapy could add $300-500M in annual revenue by 2030, with animal data expected late 2025.
- **Strong Balance Sheet**: $103M net cash surplus (vs. $75M debt) supports debt repayment and growth initiatives.


**【CEO Summary Section】**
- Total revenue for 2024 reached $426.5 million, a 65% year-over-year increase. Adjusted EBITDA grew to $164.6 million, representing a 309% increase from the prior year.
- 2025 revenue guidance revised to exceed $490 million, with adjusted EBITDA projected to surpass $225 million. 2026 targets include $605 million in revenue and $305 million in adjusted EBITDA.
- ASCENIV is expected to drive over $1 billion in annual revenue by 2030, with a 20% production yield enhancement process pending FDA approval by mid-2025.
- Third-party high-titer plasma supply contracts increased collection capacity fivefold, supporting accelerated ASCENIV production and patient access.

**【CFO Financial Commentary】**
- Q4 2024 revenue: $117.5 million (59% YoY growth). Full-year gross margin: 51.5% (vs. 34.4% in 2023), driven by higher-margin ASCENIV sales.
- Adjusted EBITDA: $48.3 million (Q4) and $164.6 million (FY2024), up 63% and 309% YoY. GAAP net income: $197.7 million (FY2024), reversing a $28.2 million loss in 2023.
- Operating cash flow reached $48 million in Q4, resulting in a net cash surplus of $103 million (vs. $75 million debt).

**【Q&A Key Highlights】**
- **Supply Chain Expansion**: Over 50% of third-party plasma centers are operational, with testing throughput increasing 20% YoY. Potential 2026 upside if yield enhancement is approved.
- **Patient Demand**: ASCENIV has penetrated 3% of the targeted PI market, with a growing queue of 1,000+ new patients waiting for treatment.
- **R&D Pipeline**: SG-001 (anti-strep therapy) could add $300-500 million in annual revenue by 2030. Animal data expected late 2025, with clinical trials potentially starting in 2026.
- **Financial Flexibility**: Net cash position of $103 million enables debt repayment and capital-efficient growth initiatives.

**【Regulatory & Operational Updates】**
- FDA dialogue on enhanced yield process is constructive, with potential approval by mid-2025. If approved, could add 20% to IG production without incremental costs.
- ASCENIV's intellectual property extends through 2035, with regulatory barriers and proprietary know-how protecting market position.
- SG-001 has issued IP protection through 2037, supporting long-term revenue potential.


ADMA

ADMA fundamentals

Earnings Call

You can ask Aime